Millendo Therapeutics, Inc.
MLND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $4,031 | $3,644 | $29,576 |
| - Cash | $7,514 | $14,280 | $21,511 | $30,268 |
| + Debt | $7,258 | $8,663 | $13,105 | $15,365 |
| Enterprise Value | – | -$1,586 | -$4,762 | $14,673 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3,359 | -$7,966 | -$10,936 | -$18,054 |
| % Margin | – | – | – | – |
| Net Income | -$3,511 | -$7,870 | -$10,860 | -$15,724 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.79 | -2.07 | -3.16 | 19.11 |
| % Growth | 61.8% | 34.5% | -116.5% | – |
| Operating Cash Flow | $16,467 | $8,036 | $0 | $19,704 |
| Capital Expenditures | $0 | $0 | $0 | -$351 |
| Free Cash Flow | $16,467 | $8,036 | $0 | $19,353 |